Patient interest fairly high for melanoma genetic risk testing

July 10, 2018

(HealthDay)—There is moderately high interest in genetic testing for melanoma risk among the general population, according to a study published in the June issue of JAMA Dermatology.

Jennifer L. Hay, Ph.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues examined interest in and uptake of MC1R testing in the general population and assessed patterns across demographic and skin cancer risk factors. Patients were randomized to either usual-care condition (National Cancer Institute skin cancer pamphlet for diverse skin types) or an MC1R test offer (following three web-based educational modules presenting the rationale, benefits, and drawbacks of MC1R testing).

The researchers found that 232 of the 499 participants randomized to MC1R testing logged on to the website, and of these, 88 percent (204 participants) requested testing and 82 percent (167 participants) returned the test kit. Race/ethnicity and education were the strongest predictors of logging on to the website (odds ratio for Hispanics versus non-Hispanic whites, 0.5; odds ratio for more than versus high school or less, 2.7). Sunburn history was the strongest predictor of ordering the test (odds ratio, 5.4, versus no sunburn history).

"There were moderately high levels of MC1R test interest and uptake in this diverse sample," the authors write. "Addressing potential barriers to testing may be warranted as genomic information becomes integrated into approaches to the precision prevention of ."

Explore further: Gender disparity observed in cancer genetic testing in the U.S.

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Gender disparity observed in cancer genetic testing in the U.S.

May 3, 2018
(HealthDay)—Specific demographic groups have lower cancer genetic testing, including unaffected men compared with unaffected women, according to a research letter published online April 26 in JAMA Oncology.

Sun defenses up in transplant patients after skin cancer study

June 13, 2018
(HealthDay)—For organ transplant recipients, participation in a skin cancer research study is associated with increased use of multiple sun protection behaviors, according to a research letter published online June 6 in ...

Disordered eating behaviors up for overweight young adults

July 8, 2018
(HealthDay)—Young adults at a weight status classified as overweight or obese have increased prevalence of disordered eating behaviors (DEBs), according to a study published online June 11 in the Journal of General Internal ...

Is there association between MC1R and melanoma risk after controlling for sun?

April 6, 2016
There is a well-described association between UV radiation exposure from the sun and the development of melanoma. The development of melanoma independent of sun exposure has only recently been described in mice.

Researchers discover why redheads are more prone to melanoma

September 6, 2017
Red-haired people are known for pale skin, freckles, poor tanning ability and unfortunately, an increased risk for developing skin cancer. Research has shown that they have variants in Melanocortin 1 Receptor (MC1R), a protein ...

Hydrochlorothiazide tied to non-melanoma skin cancer risk

March 22, 2018
(HealthDay)—Use of the diuretic hydrochlorothiazide is associated with a substantially increased risk of non-melanoma skin cancer, according to a study published in the April issue of the Journal of the American Academy ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.